Primary progressive multiple sclerosis in Iran: A consensus recommendation for diagnosis and management

Sahraian, Mohammad Ali; Baghbanian, Seyed Mohammad; Langroodi, Hamidreza Ghalyanchi; Abolfazli, Roya; Alaie, Shekoofeh; Asgari, Nasrin; Ashtari, Fereshteh; Ayromlouh, Hormoz; Moghadam, Nahid Beladi; Foroughipour, Mohsen; Majdinasab, Nastaran; Mohammadianinejad, Seyed Ehsan; Nickseresht, Alireza; Nourian, Abbas; Shahmohammadi, Sareh; Shayegannejad, Vahid; Torabi, Hamid Reza

doi:10.1016/j.msard.2018.09.013

Cited by 5 publications

(12 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13][14][15] It has shown satisfactory effects, high tolerability, and minor side effects. 13,14,[16][17][18] Few studies have evaluated the efficacy of RTX in progressive forms of MS so far. RIVITaLISe trial was designed to evaluate the efficacy of intravenous and intrathecal RTX on SPMS but was terminated early after an interim analysis that revealed insufficient changes in the pre-defined cerebrospinal fluid (CSF) biomarkers to conclude any clinical efficacy.…”

mentioning

confidence: 99%

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

et al. 2020

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease characterized by demyelination of neurons in the central nervous system. 1,2 It is the most common cause of acquired disabling neurological disorder in young population worldwide and there is an ongoing increase in its prevalence and incidence in Europe, Mediterranean, and Middle East. 3,4 Relapsing remitting MS (RRMS) accounts for nearly 85% of MS cases and might evolve into the progressive form over time. 2,5 Around 25% of RRMS patients progress to secondary progressive MS (SPMS) by 10 years, and this rate grows as the duration of disease increases. 3,6 The progressive course is characterized by cumulative deterioration of neurological impairments, with or without relapses, with infrequent unstable minor improvements or plateau phases. 2

show abstract

mentioning

confidence: 99%

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Of the 12 included publications (Table 1), five were clinical practice guidelines [18,21,[24][25][26] and seven were evidence-based recommendations [19,20,22] or statements [23,[27][28][29]. All articles were developed and published by a government entity [20,21,25], medical society [19,23,24,[26][27][28][29], or panel of domain experts [18,22]. Ten publications were financially supported by a government entity or medical society, of which three reported receiving research grants or honoraria from pharmaceutical companies [18,19,23].…”

Section: Characteristics Of the Included Publicationsmentioning

confidence: 99%

“…Ten publications were financially supported by a government entity or medical society, of which three reported receiving research grants or honoraria from pharmaceutical companies [18,19,23]. One publication was solely financed by an educational grant from a pharmaceutical company [22].…”

Section: Characteristics Of the Included Publicationsmentioning

confidence: 99%

“…One publication indicated that the intended users of their health care recommendation were both doctors and patients [21], while five others stated that their recommendation was targeted towards health care professionals only [20,23,24,28,29]. e other six articles did not state the intended users of their recommendation [18,19,22,[25][26][27].…”

Section: Characteristics Of the Included Publicationsmentioning

confidence: 99%

“…More than half of the included articles provided recommendations on neuropathic pain. Specifically, four articles addressed neuropathic pain associated with multiple sclerosis [18,19,22,25] and three addressed neuropathic pain in general [20,26,29]. Two articles were on chronic noncancer pain in general [21,28].…”

Section: Characteristics Of the Included Publicationsmentioning

confidence: 99%

See 2 more Smart Citations

Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations

Chang

Meng²,

Vannabouathong³

et al. 2021

Pain Research and Management

View full text Add to dashboard Cite

Purpose. Medical cannabis for patients with chronic noncancer pain (CNCP) has been the focus of numerous health care recommendations. We conducted a systematic review to identify and summarize the currently available evidence-based recommendations. Methods. We searched MEDLINE, EMBASE, PsycINFO, the Cochrane database of systematic reviews, and websites for clinical guidelines and recommendations. We summarized the type of the publications, developers, approach of health care recommendation development, year and country of publication, and conditions that were addressed. We categorized the direction and strength of each recommendation. Results. We identified 12 eligible publications. Publication years ranged from 2007 to 2019; four (33.3%) of them were published in 2018. Canada ranked first for the number of publications (n = 4, 33.3%). Most (n = 11, 92%) of the included recommendations were based on both a systematic review of the best evidence and expert consensus. All the included publications provided a recommendation supporting medical cannabis for CNCP in general and for the specific conditions of neuropathic pain, chronic pain in people living with Human Immunodeficiency Virus (HIV), and chronic abdominal pain, with detailed information sharing and comprehensive consideration of a patient’s own values and preferences. Conclusion. Clinicians can attend to the guidance currently offered, being aware that only weak recommendations are available for medical cannabis in patients with CNCP, as a third- or fourth-line therapy. Detailed discussions with patients regarding the benefits in reducing pain and potential adverse effects are required before its prescription.

show abstract

When an octopus has MS: Application of neurophysiology and immunology of octopuses for multiple sclerosis

Moghadasi

2019

Medical Hypotheses

View full text Add to dashboard Cite

Primary progressive multiple sclerosis in Iran: A consensus recommendation for diagnosis and management

Cited by 5 publications

References 125 publications

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

Medical Cannabis for Chronic Noncancer Pain: A Systematic Review of Health Care Recommendations

When an octopus has MS: Application of neurophysiology and immunology of octopuses for multiple sclerosis

Contact Info

Product

Resources

About